首页 > 分享 > 黄芩苷治疗脂肪性肝病药理作用的研究进展

黄芩苷治疗脂肪性肝病药理作用的研究进展

花匠小妙招
2025-07-29 07:09

[1] 赵含笑, 于天启. 黄芩苷对多发性骨髓瘤细胞株U266增殖、凋亡、侵袭的影响[J]. 山东医药, 2018, 58(47):28-31.[本文引用:1][2] 杨爱霞, 吴彪, 何伟, 等. 黄芩苷诱导小鼠结肠癌发生坏死性凋亡作用的体外研究[J]. 医药导报, 2019, 38(2):167-172.[本文引用:1][3] 黄智生, 杨斌, 张清, 等. 黄芩苷联合连翘苷对甲型流感病毒核蛋白基因表达的影响[J]. 医学研究生学报, 2018, 31(10):1033-1037.[本文引用:1][4] 刘杨, 黄媛, 廖毅, 等. 黄芩苷体外抗人巨细胞病毒活性及其对感染人胚肺成纤维细胞凋亡的影响[J]. 医药导报, 2017, 36(10):1124-1129.[本文引用:1][5] 孙磊, 黑晶, 孙涛, 等. 黄芩苷抑制脂多糖诱导的大鼠葡萄膜炎的作用与机制[J]. 宁夏医科大学学报, 2018, 40(9):1014-1016.[本文引用:1][6] 王智, 王娟, 包斯图, 等. 黄芩苷对酯多糖损伤AC16心肌细胞的保护作用及机制研究[J]. 天然产物研究与开发, 2019, 31(3):428-433.[本文引用:1][7] WANG Y, JIA Y, YANG X, et al. A potential role of Baicalin to inhibit apoptosis and protect against acute liver and kidney injury in rat preeclampsia model[J]. Biomed Pharmacother, 2018, 108:1546-1552.

DOI:10.1016/j.biopha.2018.09.107 URL

[本文引用:1][8] 胡默. 黄芩苷铜稳定性分析及其对小鼠实验性肝损伤影响的研究[D]. 重庆:西南大学, 2014:25-35.[本文引用:1][9] ZHONG X Q, LIU H L. Baicalin attenuates diet induced nonalcoholic steatohepatitis by inhibiting inflammation and oxidative stress via suppressing JNK signaling pathways[J]. Biomed Pharmacother, 2018, 98:111-117.

DOI:10.1016/j.biopha.2017.12.026 URL

[本文引用:2][10] FANG P, YU M, SHI M, et al. Baicalin and its aglycone:a novel approach for treatment of metabolic disorders[J]. Pharmacol Rep, 2020, 72(1):13-23.

DOI:10.1007/s43440-019-00024-x URL

[本文引用:1][11] ZHANG J L, ZHANG H M, DENG X L, et al. Baicalin attenuates non-alcoholic steatohepatitis by suppressing key regulators of lipid metabolism,inflammation and fibrosis in mice[J]. Life Sci, 2018, 192:46-54.

DOI:10.1016/j.lfs.2017.11.027 URL

[本文引用:2][12] CHEN Q, LIU M Y, YU H Y, et al. Scutellariabaicalensis regulates FFA metabolism to ameliorate NAFLD through the AMPK-mediated SREBP signaling pathway[J]. J Nat Med, 2018, 72(3):655-666.

DOI:10.1007/s11418-018-1199-5 URL

[本文引用:1][13] LEE H, KANG R, HAHN Y, et al. Antiobesity effect of baicalin involves the modulations of proadipogenic and antiadipogenic regulators of the adipogenesispathway[J]. Phytother Res, 2009, 23(11):1615-1623.

DOI:10.1002/ptr.2937 URL

[本文引用:2][14] LEE H, BAE S, KIM K, et al. Beta-Catenin mediates the anti-adipogenic effect of baicalin[J]. Biochem Biophys Res Commun, 2010, 398(4):741-746.

DOI:10.1016/j.bbrc.2010.07.015 URL

[本文引用:1][15] KWAK D H, LEE J H, SONG K H, et al. Inhibitory effects of baicalin in the early stage of 3T3-L1 preadipocytes differentiation by down-regulation of PDK1/Aktphosphorylation[J]. Mol Cell Biochem, 2014, 385(1/2):257-264.

DOI:10.1007/s11010-013-1834-0 URL

[本文引用:1][16] GUO H X, LIU D H, MA Y, et al. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet[J]. Acta Pharmacol Sin, 2009, 30(11):1505-1512.

DOI:10.1038/aps.2009.150 URL

[本文引用:1][17] XI Y, WU M, LI H, et al. Baicalin attenuates high fat diet-induced obesity and liver dysfunction:dose-response and potential role of CaMKKβ/AMPK/ACC pathway[J]. CellPhysiolBiochem, 2015, 35(6):2349-2359.[本文引用:2][18] XI Y L, LI H X, CHEN C, et al. Baicalin attenuates high fat diet-induced insulin resistance and ectopic fat storage in skeletal muscle,through modulating the protein kinase B/Glycogen synthase kinase 3 beta pathway[J]. Chin J Nat Med, 2016, 14(1):48-55.[本文引用:2][19] DAI J Y, LIANG K, ZHAO S, et al. Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis[J]. Proc Natl Acad Sci U S A, 2018, 115(26):E5896-E5905.

DOI:10.1073/pnas.1801745115 URL

[本文引用:1][20] 张聪, 盛磊, 杨恬, 等. 鞣花酸对AKT基因转染诱导小鼠脂肪性肝病中炎症及氧化应激的影响[J]. 中国中药杂志, 2019, 44(9):1869-1875.[本文引用:1][21] TAO J, WEI Y, HU T. Flavonoids of Polygonumhydropiper L.attenuates lipopolysaccharide-induced inflammatory injury via suppressing phosphorylation in MAPKs pathways[J]. BMC Complement Altern Med, 2016, 16:25.

DOI:10.1186/s12906-016-1001-8 URL

[本文引用:1][22] 艾正琳. 黄芩苷、苦参碱、小檗碱对NASH大鼠的治疗作用及对L-FABP的影响与机制研究[D]. 北京:北京协和医学院, 2012:13-37.[本文引用:1][23] 艾正琳, 洪珊, 胡居龙, 等. 黄芩苷治疗非酒精性脂肪性肝炎大鼠抗炎的疗效[J]. 山东大学学报(医学版), 2019, 57(7):55-60.[本文引用:1][24] 施晓敏, 石朝明. 非酒精性脂肪性肝病与2型糖尿病的相互作用机制研究进展[J]. 温州医科大学学报, 2021, 51(1):75-79.[本文引用:1][25] 李营营, 张吟. 腺苷酸活化蛋白激酶促胰岛β细胞凋亡机制的研究进展[J]. 中国现代应用药学, 2018, 35(1):143-147.[本文引用:1][26] 秦思茹, 唐慧玲, 李威, 等. AMPK 及下游靶点在黄连素防治缺血性脑卒中的作用[J/OL]. 中国现代应用药学, .

URL

[本文引用:1][27] FANG P H, YU M, ZHANG L, et al. Baicalin against obesity and insulin resistance through activation of AKT/AS160/GLUT4 pathway[J]. Mol Cell Endocrinol, 2017, 448:77-86.

DOI:10.1016/j.mce.2017.03.027 URL

[本文引用:1][28] FANG P H, SUN Y B, GU X R, et al. Baicalin ameliorates hepatic insulin resistance and gluconeogenic activity through inhibition of p38 MAPK/PGC-1α pathway[J]. Phytomedicine, 2019, 64:153074.

DOI:10.1016/j.phymed.2019.153074 URL

[本文引用:1][29] FANG P, YU M, MIN W, et al. Beneficial effect of baicalin on insulin sensitivity in a dipocytes of diet-induced obese mice[J]. Diabetes Res Clin Pract, 2018, 139:262-271.

DOI:10.1016/j.diabres.2018.03.007 URL

[本文引用:1][30] 郗有丽. 黄芩苷对高脂饮食小鼠胰岛素抵抗的影响和机制研究[D]. 南京:东南大学, 2015:36-56.[本文引用:1][31] 郗有丽, 周杰, 聂超, 等. 黄芩苷诱导自噬改善胰岛素抵抗[J]. 生物加工过程, 2019, 17(6):630-634.[本文引用:1][32] 刘娅群. 黄芩苷对2型糖尿病糖脂代谢的影响及机制研究[D]. 南京:东南大学, 2017:35-55.[本文引用:1][33] 牛乐乐, 刘晶, 常海瑶, 等. 血管生成素样蛋白6和瘦素与2型糖尿病合并非酒精性脂肪肝的相关性研究[J]. 中国全科医学, 2020, 23(S1):51-54.[本文引用:1][34] 马沛. 白藜芦醇、和厚朴酚、黄芩苷对羊肝原代细胞Angptl6 mRNA表达影响[D]. 长沙:湖南农业大学, 2011:43-55.[本文引用:1][35] 唐彬, 宋振梅, 肖琦凡. 黄芩苷对高脂-脂肪肝模型大鼠肝脏炎症改善及炎性因子表达的影响[J]. 青岛大学医学院学报, 2017, 53(6):659-663,667.[本文引用:1][36] KIM S J, LEE S M. Effect of baicalin on toll-like receptor 4-mediated ischemia/reperfusion inflammatory responses in alcoholic fatty liver condition[J]. Toxicol Appl Pharmacol, 2012, 258(1):43-50.

DOI:10.1016/j.taap.2011.10.005 URL

[本文引用:1][37] ZHANG J, ZHANG H, DENG X L, et al. Baicalin protects AML-12 cells from lipotoxicity via the suppression of ER stress and TXNIP/NLRP3 inflammasome activation[J]. ChemBiol Interact, 2017, 278:189-196.[本文引用:1][38] SHI H L, ZHANG Y L, XING J, et al. Baicalin attenuates hepatic injury in non-alcoholic steatohepatitis cell model by suppressing inflammasome-dependent GSDMD-mediated cell pyroptosis[J]. Int Immunopharmacol, 2020, 81:106195.

DOI:10.1016/j.intimp.2020.106195 URL

[本文引用:1][39] LIU J, YUAN Y Y, GONG X, et al. Baicalin and its nanoliposomesameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice[J]. Int Immunopharmacol, 2020, 80:106208.

DOI:10.1016/j.intimp.2020.106208 URL

[本文引用:1][40] 袁颖琳. 黄芩苷纳米脂质体抑制TLR4信号通路减轻小鼠非酒精性脂肪肝病[D]. 重庆:重庆大学, 2017:34-45.[本文引用:1][41] LIU J, YUAN Y L, GONG X, et al. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice[J]. Int Immunopharmacol, 2020, 80:106208.

DOI:10.1016/j.intimp.2020.106208 URL

[本文引用:2][42] HU C F, WANG Y Q, FAN Y S, et al. Lipidomics revealed idiopathic pulmonary fibrosis-induced hepatic lipid disorders corrected with treatment of baicalin in a murine model[J]. AAPS J, 2015, 17(3):711-722.

DOI:10.1208/s12248-014-9714-4 URL

[本文引用:2][43] WU T, LIU T, XING L J, et al. Baicalin and puerarin reverse epithelial-mesenchymal transition via the TGF-β1/Smad3 pathway in vitro[J]. ExpTher Med, 2018, 16(3):1968-1974.[本文引用:1]